222 related articles for article (PubMed ID: 36321611)
21. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
[TBL] [Abstract][Full Text] [Related]
22. TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment.
Zhu H; Hu X; Gu L; Jian Z; Li L; Hu S; Qiu S; Xiong X
Front Genet; 2021; 12():759953. PubMed ID: 34721547
[TBL] [Abstract][Full Text] [Related]
23. Identification of tumor microenvironment-related genes in lower-grade gliomas by mining TCGA database.
Liang H; Huang C
Transl Cancer Res; 2020 Aug; 9(8):4583-4595. PubMed ID: 35117823
[TBL] [Abstract][Full Text] [Related]
24. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
25. Potential role of POFUT1 as a prognostic predictor in low-grade gliomas: Immune microenvironment insights from a pan-cancer analysis.
Yu F; Lou S; He H; Zhou Y
Heliyon; 2024 Mar; 10(5):e27004. PubMed ID: 38463813
[TBL] [Abstract][Full Text] [Related]
26. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
27. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
28. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas.
Wang M; Jia J; Cui Y; Peng Y; Jiang Y
Brain Sci; 2021 Nov; 11(11):. PubMed ID: 34827528
[No Abstract] [Full Text] [Related]
29. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
30. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
[TBL] [Abstract][Full Text] [Related]
31. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
[TBL] [Abstract][Full Text] [Related]
32. Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase Family: Novel Prognostic Biomarkers and Tumor Microenvironment Regulators for Lower-Grade Glioma.
Gong S; Wu C; Köhler F; Meixensberger J; Schopow N; Kallendrusch S
Front Cell Neurosci; 2022; 16():838548. PubMed ID: 35250490
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas.
Fang Z; Lin L; Tu Z; Zhu X; Li J; Luo P; Huang K; Wu L
Cancer Med; 2023 Jan; 12(1):712-732. PubMed ID: 35702880
[TBL] [Abstract][Full Text] [Related]
34. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas.
Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J
Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988
[No Abstract] [Full Text] [Related]
35. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of chromatin regulator-related signatures as a novel prognostic model for low-grade gliomas using translational bioinformatics.
Wang B; Feng Y; Li Z; Zhou F; Luo J; Yang B; Long S; Li X; Liu Z; Li X; Chen J; Wang L; Wei W
Life Sci; 2024 Jan; 336():122312. PubMed ID: 38042284
[TBL] [Abstract][Full Text] [Related]
37. Pyroptosis-Related Genes as Markers for Identifying Prognosis and Microenvironment in Low-Grade Glioma.
Han J; Jing Y; Sun P
J Healthc Eng; 2023; 2023():6603151. PubMed ID: 36820395
[TBL] [Abstract][Full Text] [Related]
38. Identification of natural killer cell-related characteristics to predict the clinical prognosis and immune microenvironment of patients with low-grade glioma.
Sun F; Lv H; Feng B; Sun J; Zhang L; Dong B
Aging (Albany NY); 2023 Jul; 15(13):6264-6291. PubMed ID: 37405952
[TBL] [Abstract][Full Text] [Related]
39. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
40. Identification of COL1A1 associated with immune infiltration in brain lower grade glioma.
Ren J; Da J; Hu N
PLoS One; 2022; 17(7):e0269533. PubMed ID: 35789341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
